Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
Publication
, Journal Article
West, AB
Published in: Mov Disord
February 2015
The burden that Parkinson's disease (PD) exacts on the population continues to increase year after year. Though refinement of symptomatic treatments continues at a reasonable pace, no accepted therapies are available to slow or prevent disease progression. The leucine-rich repeat kinase 2 (LRRK2) gene was identified in PD genetic studies and offers new hope for novel therapeutic approaches. The evidence linking LRRK2 kinase activity to PD susceptibility is presented, as well as seminal discoveries relevant to the prosecution of LRRK2 kinase inhibition. Finally, suggestions are made for predictive preclinical modeling and successful first-in-human trials.
Duke Scholars
Published In
Mov Disord
DOI
EISSN
1531-8257
Publication Date
February 2015
Volume
30
Issue
2
Start / End Page
180 / 189
Location
United States
Related Subject Headings
- Protein Serine-Threonine Kinases
- Parkinson Disease
- Neuroprotective Agents
- Neurology & Neurosurgery
- Mutation
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
- Humans
- Animals
- 3209 Neurosciences
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
West, A. B. (2015). Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord, 30(2), 180–189. https://doi.org/10.1002/mds.26075
West, Andrew B. “Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.” Mov Disord 30, no. 2 (February 2015): 180–89. https://doi.org/10.1002/mds.26075.
West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord. 2015 Feb;30(2):180–9.
West, Andrew B. “Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.” Mov Disord, vol. 30, no. 2, Feb. 2015, pp. 180–89. Pubmed, doi:10.1002/mds.26075.
West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord. 2015 Feb;30(2):180–189.
Published In
Mov Disord
DOI
EISSN
1531-8257
Publication Date
February 2015
Volume
30
Issue
2
Start / End Page
180 / 189
Location
United States
Related Subject Headings
- Protein Serine-Threonine Kinases
- Parkinson Disease
- Neuroprotective Agents
- Neurology & Neurosurgery
- Mutation
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
- Humans
- Animals
- 3209 Neurosciences
- 3202 Clinical sciences